Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The brokerage presently has a $15.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 14.50% from the company’s current price.

According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “

Several other research firms have also recently commented on AQXP. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald set a $28.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 9th. Finally, ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.25.

Aquinox Pharmaceuticals (AQXP) traded down 3.32% during trading on Thursday, reaching $13.10. 46,374 shares of the company’s stock were exchanged. Aquinox Pharmaceuticals has a 12 month low of $8.76 and a 12 month high of $19.97. The stock’s market cap is $307.12 million. The firm has a 50 day moving average of $14.58 and a 200-day moving average of $15.51.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the consensus estimate of ($0.59). On average, equities research analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Upgraded by Zacks Investment Research to Buy” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/aquinox-pharmaceuticals-inc-nasdaqaqxp-upgraded-by-zacks-investment-research-to-buy.html.

In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $13.26, for a total value of $207,187.50. Following the transaction, the insider now directly owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Investment Centers of America Inc. purchased a new position in shares of Aquinox Pharmaceuticals during the first quarter valued at about $172,000. Archon Partners LLC boosted its position in shares of Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Aquinox Pharmaceuticals during the second quarter valued at about $874,000. 98.32% of the stock is currently owned by institutional investors and hedge funds.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Get a free copy of the Zacks research report on Aquinox Pharmaceuticals (AQXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.